| |
 | | |
|
|
|
Developments:
Pharmaceutical giant GSK is about to make its new Globorix vaccine for meningitis A and C available at low cost in Africa. Although the company will not sell the vaccine anywhere else and is therefore unlikely to recoup its research costs, let alone make a profit, activists still complain.
|
| | | |